Mereo Story

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;'>MB</div>
MREO -- USA Stock  

USD 3.18  0.09  2.75%

While some baby boomers are getting worried about healthcare space, it is reasonable to outline Mereo Biopharma Group. Why are we still confident in anticipation of a complete recovery. Is the firm valuation justified? Here we go over Mereo Biopharma Group perspective on valuation to give you a better outlook on taking a position in this stock.
Published over a month ago
View all stories for Mereo Biopharma | View All Stories
Our prognosis on Mereo Biopharma (NASDAQ:MREO) to bounce back in January
This firm currently holds 1.22 M in liabilities with Debt to Equity (D/E) ratio of 1.64, which is about average as compared to similar companies. The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Mereo Biopharma has an asset utilization ratio of 101.61 percent. This suggests that the company is making $1.02 for each dollar of assets. An increasing asset utilization means that Mereo Biopharma Group is more efficient with each dollar of assets it utilizes for everyday operations.
We determine the current worth of Mereo Biopharma Group using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Mereo Biopharma Group based exclusively on its fundamental and basic technical indicators. By analyzing Mereo Biopharma's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Mereo Biopharma's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Mereo Biopharma. We calculate exposure to Mereo Biopharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Mereo Biopharma's related companies.

Mereo Biopharma Group Investment Alerts

Mereo investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Mereo Biopharma Group performance across your portfolios.Please check all investment alerts for Mereo

Mereo Biopharma Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Mereo value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Mereo Biopharma competition to find correlations between indicators driving the intrinsic value of Mereo.

How Mereo utilizes its cash?

To perform a cash flow analysis of Mereo Biopharma, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Mereo Biopharma is receiving and how much cash it distributes out in a given period. The Mereo Biopharma cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Mereo Biopharma Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (44.6 Million)

A Deeper look at Mereo

The company reported the previous year's revenue of 507.03 K. Net Loss for the year was (489.97 K) with profit before overhead, payroll, taxes, and interest of 112 K.

Mereo Biopharma Earnings Before Interest Taxes and Depreciation Amortization USD is decreasing over the last 5 years. Moreover, Mereo Biopharma Free Cash Flow is decreasing over the last 5 years. The latest value of Mereo Biopharma Free Cash Flow is -49,579,789.

Our take on today Mereo Biopharma rise

The risk adjusted performance is down to -0.16 as of today. Mereo Biopharma Group exhibits very low volatility with skewness of 0.01 and kurtosis of 0.73. However, we advise investors to further study Mereo Biopharma Group technical indicators to make sure all market info is available and is reliable.

Our Takeaway on Mereo Biopharma Investment

Whereas many other companies under the biotechnology industry are still a bit expensive, Mereo Biopharma may offer a potential longer-term growth to institutional investors. While some institutional investors may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Mereo Biopharma.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Mereo Biopharma Group. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com